Athira Pharmaincis A Clinical Stage Biopharmaceutical Company Based In Bothellwashingtonfounded In 2011 And Formerly Known As M3 Biotechnologythe Company Focuses On Advancing Therapies For Neuronal Healthathira Pharma Is Publicly Traded On Nasdaq Under The Ticker Symbol Atha The Company S Mission Is To Restore Lives By Developing Small Molecules Aimed At Treating Neurological Disorders And Slowing Neurodegenerationathira S Product Pipeline Includes Several Drug Candidatessuch As Ath 1017Which Is In Phase 2 3 Clinical Trials For Alzheimer S Diseaseand Ath 1105Currently In Phase 1 Trials For Amyotrophic Lateral Sclerosisals The Company Utilizes Proprietary Neurotrophic Factor Technology To Create Innovative Therapeutic Solutions For Neurodegenerative Diseases
